Anti-Human CD73 (NT5E) (Clone CPTC-NT5E-1) – Purified No Carrier Protein

Synthetic peptide VIYPAVEGR

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0966B-2F7-H2/K3 activity is directed against human NT5E (CD73) peptide sequence VIYPAVEGR.

CPTC-NT5E-1

NT5E (CD73) is a membrane-bound ecto-nucleotidase expressed on cell surfaces that acts as the rate-limiting step in the catabolism of extracellular ATP to adenosine^1,2. NT5E also plays a critical role in maintaining immune homeostasis. NT5E catalytic activity is responsible for the conversion of adenosine monophosphate (AMP) to adenosine by dephosphorylation. The free adenosine generated by NT5E inhibits cellular immune responses and can promote immune escape of tumor cells. In this way, NT5E acts as an inhibitory immune checkpoint molecule.

When properly regulated, NT5E-derived adenosine mediates immunosuppression and anti- inflammatory effects by activating the adenosine A2A receptor expressed by natural killer cells, T cells, and dendritic cells and blocking their effector functions^1,2. However, when cancer cells abnormally upregulate NT5E activity, they can evade immune surveillance and promote proliferation, metastasis, and angiogenesis. NT5E blockade is therefore being investigated for the treatment of cancer.

Other roles for NT5E include regulating epithelial ion transport, preserving mucosal hydration, sealing gaps between vascular endothelial cells created by transmigrating neutrophils, and protecting fetuses from maternal immune attack during pregnancy¹.

EB0966B-2F7-H2/K3 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human NT5E, VIYPAVEGR³. EB0966B-2F7-H2/K3 does not detect NT5E by immunohistochemistry, immunofluorescence, or indirect ELISA⁴.

NT5E is expressed on the cell surface of many tissues, including epithelial cells of the respiratory tract, smooth muscle cells, and cardiac myocytes. NT5E is also found on regulatory T cells, anergic CD4+ T cells, and lymphocytes. NT5E is widely expressed in many cancers, including breast, colorectal, glioblastoma, melanoma, prostrate, ovarian, and non-small-cell lung cancer.

AP-2, c-AMP responsive elements

1 Kordaß T, Osen W, Eichmüller SB. Front Immunol. 9:813. 2018.
2 Jiang T, Xu X, Qiao M, et al. BMC Cancer. 18(1):267. 2018.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-NT5E-1#CPTC-NT5E-1